Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

NCT: NCT07816185 · RECRUITING

NCT IDNCT07816185
StatusRECRUITING
Start Date2026-08-31
Completion2029-08-31
SponsorPulmovant, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑